drugset / Trial / NCT00219167

A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

NCT00219167

Phase 3 Completed 355 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks

Timeline

Start
2005-04
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 75 mg Oral
Subject Aliskiren Small molecule 150 mg Oral
Subject Aliskiren Small molecule 300 mg Oral